心脉医疗(688016) - 2024-004投资者关系活动记录表

Financial Performance - In the first half of 2024, the company achieved operating revenue of 787.17 million RMB, a year-on-year increase of 26.63% [2] - Net profit attributable to shareholders reached 403.52 million RMB, up 44.46% compared to the same period last year [2] - Basic earnings per share were 3.27 RMB, reflecting a growth of 25.29% year-on-year [2] - The company distributed a cash dividend of 16.50 RMB per 10 shares, totaling 203.38 million RMB, which accounts for 50.40% of the net profit attributable to shareholders for the first half of 2024 [2] Market Expansion - The domestic market coverage has increased, with the Castor branched aortic stent and delivery system covering over 1,100 hospitals and over 25,000 implants [3] - The Minos abdominal aortic stent and delivery system has reached nearly 900 hospitals [3] - The Reewarm PTX drug balloon dilation catheter has covered over 1,000 hospitals [3] - Internationally, overseas sales revenue grew by over 65% compared to the previous year, with 8 new overseas product registrations obtained [3] Research and Development Progress - The L-REBOA® aortic occlusion balloon catheter has received medical device registration from the National Medical Products Administration [4] - The Cratos® branched aortic stent and delivery system has obtained EU custom certification and is undergoing pre-market clinical trials in Europe [4] - The Aegis® II abdominal aortic stent system has completed clinical implants, while the multi-branch stent system is in the follow-up phase [5] Product Development and Regulatory Approvals - The Cratos® branched aortic stent system is in the registration application phase in China, expected to receive certification in Q1 2025 [6] - The company has launched several new products, including the Aorfix™ abdominal aortic stent system and the Altura™ abdominal aortic stent system [7] - The company is actively pursuing strategic partnerships to enhance its product offerings in the vascular intervention market [5] Pricing and Market Strategy - The terminal pricing for the company's aortic stent products has been adjusted in accordance with national healthcare pricing guidelines [8] - The company is focusing on expanding its peripheral market strategy, with several products expected to receive certification in the near future [8] - The integration of OMD is underway, with plans to enhance overseas business investments [9]